Generic Name and Formulations:
Fosaprepitant dimeglumine (prodrug of aprepitant) 115mg/vial, 150mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains polysorbate 80.
Company:
Merck & Co., Inc.
Indications for EMEND INJECTION:
In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.
Adult:
≥18yrs: Give with corticosteroid and 5-HT3 antagonist (see literature). Give approx. 30min prior to chemotherapy. Highly emetogenic: Single-dose regimen: 150mg IV over 20–30min on Day 1. Moderately or highly emetogenic: 3-Day regimen: 115mg IV over 15 min on Day 1, then Days 2 and 3: 80mg orally once daily in the AM.
Children:
<18yrs: not recommended.
See Also:
EMEND
Contraindications:
Concomitant pimozide, cisapride.
Warnings/Precautions:
Not for chronic continuous use. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.
Interactions:
See Contraindications. Monitor, and caution with, CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine); CYP3A4 inhibitors (eg, azole antifungals, macrolides, nefazodone, ritonavir, nelfinavir, diltiazem); and with CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each regimen); phenytoin, tolbutamide, other CYP2C9 substrates; paroxetine, oral contraceptives (use alternative or backup method during and for 1 month after last dose).
Adverse Reactions:
Asthenia, fatigue, hiccups, ALT/AST increased, headache, constipation, anorexia, GI upset, eructation, hypotension, pruritus, pyrexia. Injection: inj site pain.
How Supplied:
Caps 40mg—1; Bi-fold pack (2 x 80mg)—1; Tri-fold pack (1 x 125mg + 2 x 80mg)—1; Vial—1